Get the Stockscreener App
7.77
3.60%
0.27
After Hours:
7.77
Iteos Therapeutics Inc stock is traded at $7.77, with a volume of 366.46K.
It is up +3.60% in the last 24 hours and up +34.66% over the past month.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.
See More
Previous Close:
$7.50
Open:
$7.54
24h Volume:
366.46K
Relative Volume:
0.95
Market Cap:
$281.31M
Revenue:
$127.70M
Net Income/Loss:
$-121.25M
P/E Ratio:
-2.4667
EPS:
-3.15
Net Cash Flow:
$-120.32M
1W Performance:
+5.71%
1M Performance:
+34.66%
6M Performance:
-11.80%
1Y Performance:
-32.38%
1-Day Range:
$7.42
$7.80
1-Week Range:
$6.58
$7.80
52-Week Range:
$4.80
$18.75
Iteos Therapeutics Inc Stock (ITOS) Company Profile
Name
Iteos Therapeutics Inc
Sector
Industry
Phone
857-204-4583
Address
321 ARSENAL STREET, WATERTOWN
Compare ITOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ITOS
Iteos Therapeutics Inc
|
7.77 | 281.31M | 127.70M | -121.25M | -120.32M | -3.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Iteos Therapeutics Inc Stock (ITOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Initiated | Wells Fargo | Overweight |
| May-05-21 | Initiated | H.C. Wainwright | Buy |
| Oct-08-20 | Initiated | Robert W. Baird | Outperform |
| Aug-18-20 | Initiated | JP Morgan | Overweight |
| Aug-18-20 | Initiated | Piper Sandler | Overweight |
| Aug-18-20 | Initiated | SVB Leerink | Outperform |
| Aug-18-20 | Initiated | Wedbush | Outperform |
View All
Iteos Therapeutics Inc Stock (ITOS) Latest News
(ITOS) Investment Analysis - news.stocktradersdaily.com
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High? - Yahoo Finance
iTeos Therapeutics (ITOS) Expected to Announce Quarterly Earnings on Friday - Defense World
Q2 EPS Estimates for iTeos Therapeutics Lowered by Wedbush - Defense World
Market Watch: ITeos Therapeutics Inc (ITOS)’s Noteworthy Gain, Closing at 7.25 - DWinneX
Chief Financial Officer Gall Matthew acquire 5,000 shares of ITeos Therapeutics Inc [ITOS] - knoxdaily.com
ITeos Therapeutics Inc (ITOS) produces promising results - uspostnews.com
iTeos Therapeutics Reports Q1 2025 Financial Results - TipRanks
iTeos meldet Finanzergebnisse für das erste Quartal 2025 und gibt aktuelle Geschäftsinformationen bekannt - GlobeNewswire Inc.
iTeos meldet Finanzergebnisse für das erste Quartal 2025 und gibt aktuelle Geschäftsinformationen bekannt - GlobeNewswire
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates | ITOS Stock News - GuruFocus
iTeos Therapeutics (ITOS) Receives Adjusted Price Target from We - GuruFocus
iTeos Therapeutics stock rises as Q1 loss narrows, beats estimates By Investing.com - Investing.com Nigeria
iTeos (ITOS) Progresses with Promising Results from GALAXIES Lun - GuruFocus
iTeos Therapeutics stock rises as Q1 loss narrows, beats estimates - Investing.com
iTeos Therapeutics Reports Upcoming Interim Data from Multiple Clinical Trials and Financial Results for Q1 2025 - Nasdaq
iTeos Therapeutics, Inc. SEC 10-Q Report - TradingView
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
Analysts Say That ITeos Therapeutics Inc (NASDAQ:ITOS) Is Likely To Make It To 17 In 12 Months - Marketing Sentinel
Stock Performance Spotlight: ITeos Therapeutics Inc (ITOS) Ends the Day at 7.15, Down by -4.03 - DWinneX
Chief Financial Officer Gall Matthew acquired 5,000 shares of ITeos Therapeutics Inc [ITOS] - knoxdaily.com
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Russell Investments Group Ltd. - Defense World
Form DEFA14A iTeos Therapeutics, Inc. - StreetInsider
ITeos Therapeutics Inc (ITOS) Stock: From Low to High in 52 Weeks - investchronicle.com
There is no doubt that ITeos Therapeutics Inc (ITOS) ticks all the boxes. - Sete News
ITeos Therapeutics Inc (ITOS) stock on the rise: An overview - uspostnews.com
ITeos Therapeutics Inc [ITOS] Insider Activity: An Update for Investors - knoxdaily.com
Head-To-Head Contrast: iTeos Therapeutics (NASDAQ:ITOS) & Invizyne Technologies (NASDAQ:IZTC) - Defense World
Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year - Yahoo Finance
(ITOS) On The My Stocks Page - news.stocktradersdaily.com
Behind ITeos Therapeutics Inc’s 52-Week Range: Uncovering Opportunities for Investors - investchronicle.com
Wellington Management Group LLP Purchases 4,563 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
American Century Companies Inc. Has $522,000 Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
KLP Kapitalforvaltning AS Acquires New Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Raymond James Financial Inc. Buys New Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics stock hits 52-week low at $5.56 amid market challenges - Investing.com Australia
Iteos Therapeutics stock hits 52-week low at $5.56 amid market challenges By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
iTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Virtu Financial LLC - Defense World
Charles Schwab Investment Management Inc. Sells 22,939 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Charles Schwab Investment Management Inc. Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - The AM Reporter
Bank of New York Mellon Corp Sells 35,918 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Iteos Therapeutics Inc Stock: Cancer Drug Pipeline Shows Promise - Sharewise
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewswire
Long Term Trading Analysis for (ITOS) - news.stocktradersdaily.com
Victory Capital Management Inc. Has $782,000 Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
US Bancorp DE Acquires 4,843 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet - Yahoo Finance
(ITOS) Investment Report - news.stocktradersdaily.com
Research Analysts Offer Predictions for ITOS Q1 Earnings - Defense World
Analysts Set Expectations for ITOS FY2029 Earnings - Defense World
Iteos Therapeutics Inc Stock (ITOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):